Mode
Text Size
Log in / Sign up
N/A N=38 Treatment

Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use

Partial Edentulism · Complete Edentulism

Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Apr 2016
Primary outcome: Primary: Marginal Bone Remodeling — -1.34; -1.38; -1.37; -1.65 mm

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Shorty implants (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Nobel Biocare
Primary completion
Dec 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Marginal Bone Remodeling
-1.34; -1.38; -1.37; -1.65
SECONDARY
Cumulative Survival Rates of the Implants
96.5; 97.7; 98.8; 98.8

Summary

The aim of this study was to evaluate the 7 mm long implants NobelSpeedy Shorty and Brånemark System Mk III Shorty: by determining the marginal bone remodeling, implant survival rate, soft tissue health and maintenance.

Eligibility Criteria

Inclusion Criteria

  • The subjects should have an osseous architecture enough to receive an implant with a diameter of at least 3.75 mm for Brånemark System Mk III Shorty or 4 mm for NobelSpeedy Shorty and a sufficient amount of bone for placing implants with a length of 7 mm.
  • The final tightening torque at installation should be 35-45 Ncm without further rotation and should not exceed 45 Ncm.
  • The subject as well as the implant site(s) should fulfill criteria for immediate provizionalization.
  • Immediate insertion (e.g. placement of the implant immediately after extraction) will not constitute an exclusion criterion.
  • The implants site(s) should be free from extraction remnants.
  • The subject should be healthy and compliant with good oral hygiene.
  • The subject should be available for the 5-year term of the investigation.
  • Favorable and stable occlusal relationship

Exclusion Criteria

  • Alcohol or drug abuse as noted in patient records or in patient history.
  • Health conditions, which do not permit the surgical procedure.
  • Reason to believe that the treatment might have a negative effect on the subject's total situation (psychiatric problems), as noted in patient records or in patient history.
  • The subject is not able to give her/his informed consent to participate.
  • Any disorders in the planned implant area such as previous tumors, chronic bone disease, or previous irradiation.
  • Severe bruxism or other destructive habits.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02180230). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search